ADC Therapeutics announced a 30% workforce reduction and the closure of its UK R&D facility after halting development of multiple preclinical and clinical candidates due to limited efficacy and strategic refocus. These measures reflect ongoing challenges in oncology drug development and financial pressures impacting mid-stage biopharma companies.